1. Pink Sheet
  2. >>Legal & IP

Weight Loss, Diabetes Treatments Focus Of FTC's Second Round Of Patent Listing Challenges

 
• By Sue Sutter

The Pink Sheet takes a deep dive into the Federal Trade Commission's second wave of challenges to patents it asserts are improperly listed in the FDA's Orange Book, including patents covering Novo Nordisk's self-injection pens for Saxenda (liraglutide) and Ozempic (semaglutide).

Boxing ring
The FTC's second round of patent listing challenges targets popular self-injectable treatments for weight management and diabetes. • Source: Shutterstock

The US Federal Trade Commission’s second round of challenges to Orange Book-listed drug product patents moves the battle over listing criteria into the high-profile diabetes and weight loss therapeutic categories.

The FTC recently sent warning letters to 10 companies challenging the listing of 130 patents for 20 branded products indicated for treating asthma, chronic obstructive pulmonary disease,

Key Takeaways

  • The FTC's second round of patent listing challenges encompasses 130 patents for 20 branded products.

  • The commission is moving beyond asthma and COPD inhalers to also challenge listed patents for self-injection pens to treat diabetes and obesity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.